Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05215171 · ClinicalTrials.gov registry record

World Trade Center Particulate Matter Induced Cardiorespiratory and Vascular Dysfunction: a MultiOmic Approach (CaRVD)

A clinical trial of Cardiorespiratory and Vascular Dysfunction and Obstructive Airway Disease, sponsored by NYU Langone Health.

Recruiting
Registry status
100
Enrollment target
1
Study location

NCT05215171: Recruiting study of Cardiorespiratory and Vascular Dysfunction and Obstructive Airway Disease, sponsored by NYU Langone Health.

NCT05215171 is a study of Cardiorespiratory and Vascular Dysfunction and Obstructive Airway Disease that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 100 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05215171, a study of Cardiorespiratory and Vascular Dysfunction and Obstructive Airway Disease, is actively recruiting participants, sponsored by NYU Langone Health.

RECRUITING
Registry status
100 participants
Enrollment target
1
Study location

Study Summary

Particulate matter (PM) associated cardiorespiratory and vascular dysfunction (CaRVD) poses a significant global health burden. The World Trade Center (WTC) destruction on September 11, 2001 led to an intense deposition of particulate matter (WTC-PM) into aerodigestive system. WTC associated morbidities include respiratory, gastrointestinal, chronic rhinosinusitis, cancer, mental health concerns and more recently a focus has been on cardiovascular disease. This proposal will investigate the development of WTC-cardiorespiratory and vascular dysfunction (WTC-CaRVD) which is firmly within the purview of the James Zadroga 9/11 Health and Compensation Act. WTC-PM exposure causes heterogeneous obstructive airways disease (OAD) patterns, which include airway hyperreactivity (AHR) and loss of FEV1. Early diagnosis and therapeutic options are few, in part due to limited understanding of their pathogenesis. While pulmonary vascular changes are classically thought to occur due to the hypoxemia of late OAD, recent investigations show that vascular dysfunction occurs early in OAD. This vascular hypothesis of OAD postulates that pulmonary vasculature remodeling leads to loss of lung function. Early evidence of WTC-CaRVD includes increased prevalence of cardiovascular disease risk factors such as metabolic syndrome, elevated pulmonary artery/aorta ratio, and cardiovascular biomarkers (such as CRP). Murine models of WTC-PM exposure show inflammation, AHR both acutely and persistently and reflect what is seen in FDNY 1st responders. Airway and cardiac remodeling were also persistent features of WTC-PM exposure in the study team's murine models. Therefore, the study team will focus on Heme Oxygenase-1 (HO-1), a mediator of oxidative stress, known to stimulate collagen formation and is also induced after WTC-PM exposure. Furthermore, pathways and mechanisms of WTC-CaRVD warrant further study and are the focus of the 5-year proposal. The HYPOTHESIS is that WTC-PM exposure causes WTC-

Primary Outcome

All serum will be thawed once and assayed for biomarkers

Study Locations (1)

New York

  • NYU Clinical & Translational Science Institute Clinical Research Center (CTSI CRC) - New York

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2023-03-30
Est. Completion 2027-06
NYU Langone Health

1,164 total trials

What NCT05215171 shows while recruiting

NCT05215171 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap.

The record links to 2 conditions, with Cardiorespiratory and Vascular Dysfunction appearing as the primary indexed condition, and to 0 interventions.

NCT05215171 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT05215171 about?

NCT05215171 is a clinical study titled "World Trade Center Particulate Matter Induced Cardiorespiratory and Vascular Dysfunction: a MultiOmic Approach (CaRVD)". Particulate matter (PM) associated cardiorespiratory and vascular dysfunction (CaRVD) poses a significant global health burden. The World Trade Center (WTC) destruction on September 11, 2001 led to an intense deposition of particulate matter (WTC-PM) into aerodigestive system. WTC associated morbidi...

What is the current status of trial NCT05215171?

This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2023-03-30. Estimated completion is 2027-06.

What conditions does trial NCT05215171 study?

This clinical trial studies the following conditions: Cardiorespiratory and Vascular Dysfunction, Obstructive Airway Disease.

Who is sponsoring clinical trial NCT05215171?

This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05215171 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05215171, the US trial registry maintained by the National Library of Medicine. NCT05215171 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.